{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:42:29Z","timestamp":1789051349704,"version":"build-2803163510"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The sphingosine 1-phosphate (S1P) signaling pathway has important and diverse functions. S1P receptors (S1PRs) are involved in the regulation of lymphocyte trafficking, cardio-cerebral function, vascular permeability, and bronchiolar tone, and have been recognized as therapeutic targets for a variety of diseases. A number of drugs related to the S1P signaling pathway have been approved for clinical use in the treatment of multiple sclerosis, and many similar drugs are also currently being tested in clinical trials at various stages. It appears that S1PR modulators may not only be useful for the treatment of multiple sclerosis, but may also have therapeutic effects on other types of central nervous system (CNS) disorders. The present review focuses on the therapeutic potential of S1PR1 modulators for treating disorders of the CNS.<\/jats:p>","DOI":"10.3389\/fphar.2025.1516991","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:40:20Z","timestamp":1747186820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders"],"prefix":"10.3389","volume":"16","author":[{"given":"Shouming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/10600280221140480","article-title":"Ponesimod: an oral second-generation selective sphingosine 1-phosphate receptor modulator for the treatment of multiple sclerosis","volume":"57","author":"Alnaif","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11910-023-01282-2","article-title":"Neuroinflammation in acute ischemic and hemorrhagic stroke","volume":"23","author":"Alsbrook","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12017-019-08558-2","article-title":"Beneficial effects of fingolimod in alzheimer's disease: molecular mechanisms and therapeutic potential","volume":"21","author":"Angelopoulou","year":"2019","journal-title":"Neuromolecular Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e00972","DOI":"10.1002\/prp2.972","article-title":"The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: a systematic review and meta-analysis","volume":"10","author":"Bai","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2020_404","article-title":"Structure and function of the blood-brain barrier (BBB)","volume":"273","author":"Benz","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mus.25733","article-title":"Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability","volume":"56","author":"Berry","year":"2017","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1161\/STROKEAHA.119.027134","article-title":"Siponimod (BAF-312) attenuates perihemorrhagic edema and improves survival in experimental intracerebral hemorrhage","volume":"50","author":"Bobinger","year":"2019","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1161\/STROKEAHA.116.015371","article-title":"Selective sphingosine 1-phosphate receptor 1 agonist is protective against ischemia\/reperfusion in mice","volume":"47","author":"Brait","year":"2016","journal-title":"Stroke"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(20)31179-X","article-title":"Stroke","volume":"396","author":"Campbell","year":"2020","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/cells10113217","article-title":"Signaling through the S1P-S1PR Axis in the gut, the immune and the central nervous system in multiple sclerosis: implication for pathogenesis and treatment","volume":"10","author":"Chatzikonstantinou","year":"2021","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"113341","DOI":"10.1016\/j.biopha.2022.113341","article-title":"Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases","volume":"153","author":"Chen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1002332","DOI":"10.1371\/journal.pmed.1002332","article-title":"Trends in traumatic brain injury mortality in China, 2006-2013: a population-based longitudinal study","volume":"14","author":"Cheng","year":"2017","journal-title":"PLoS Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pr.110.003111","article-title":"International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.prostaglandins.2009.04.002","article-title":"Sphingosine-1-phosphate and oligodendrocytes: from cell development to the treatment of multiple sclerosis","volume":"91","author":"Coelho","year":"2010","journal-title":"Prostagl. Other Lipid Mediat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1089\/neu.2017.5391","article-title":"Sphingosine 1-phosphate receptor subtype 1 as a therapeutic target for brain trauma","volume":"35","author":"Cuzzocrea","year":"2018","journal-title":"J. Neurotrauma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/hmg\/ddy153","article-title":"Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease","volume":"27","author":"Di Pardo","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e61988","DOI":"10.1371\/journal.pone.0061988","article-title":"Fingolimod phosphate attenuates oligomeric amyloid \u03b2-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons","volume":"8","author":"Doi","year":"2013","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12974-024-03118-3","article-title":"Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies","volume":"21","author":"El Baassiri","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B28","doi-asserted-by":"publisher","first-page":"18315","DOI":"10.1073\/pnas.1416166111","article-title":"Impact of an immune modulator fingolimod on acute ischemic stroke","volume":"111","author":"Fu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbrc.2012.02.096","article-title":"Blocking S1P interaction with S1P1 receptor by a novel competitive S1P1-selective antagonist inhibits angiogenesis","volume":"419","author":"Fujii","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/ni.2730","article-title":"Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation","volume":"14","author":"Garris","year":"2013","journal-title":"Nat. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22074\/cellj.2016.4867","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-019-00675-7","article-title":"Fingolimod increases brain-derived neurotrophic factor level secretion from circulating T cells of patients with multiple sclerosis","volume":"33","author":"Golan","year":"2019","journal-title":"CNS Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/j.pain.0000000000000965","article-title":"Targeting the S1P\/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation","volume":"158","author":"Grenald","year":"2017","journal-title":"Pain"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1161\/STROKEAHA.109.568899","article-title":"Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats","volume":"41","author":"Hasegawa","year":"2010","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semcdb.2004.05.002","article-title":"Physiological and pathological actions of sphingosine 1-phosphate","volume":"15","author":"Hla","year":"2004","journal-title":"Semin. Cell. Dev. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bbalip.2008.07.003","article-title":"The vascular S1P gradient-cellular sources and biological significance","volume":"1781","author":"Hla","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e22616","DOI":"10.1096\/fj.202200533RR","article-title":"Sphingosine-1-phosphate receptor modulation improves neurogenesis and functional recovery after stroke","volume":"36","author":"Huang","year":"2022","journal-title":"FASEB J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0138029","DOI":"10.1371\/journal.pone.0138029","article-title":"Sphingosine-1-Phosphate receptor-1 selective agonist enhances collateral growth and protects against subsequent stroke","volume":"10","author":"Ichijo","year":"2015","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.11.040","article-title":"Sphingosine-1-Phosphate receptor 1 activation enhances leptomeningeal collateral development and improves outcome after stroke in mice","volume":"27","author":"Iwasawa","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1084\/jem.20090525","article-title":"T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"J. Exp. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"41734","DOI":"10.1038\/srep41734","article-title":"Fingolimod limits acute a\u03b2 neurotoxicity and promotes synaptic versus extrasynaptic NMDA receptor functionality in hippocampal neurons","volume":"7","author":"Joshi","year":"2017","journal-title":"Sci. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"148171","DOI":"10.1016\/j.brainres.2022.148171","article-title":"Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease","volume":"1799","author":"Jung","year":"2023","journal-title":"Brain Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1161\/STROKEAHA.108.514612","article-title":"Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain","volume":"39","author":"Kimura","year":"2008","journal-title":"Stroke"},{"key":"B47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41582-023-00801-6","article-title":"Inflammation in multiple sclerosis: consequences for remyelination and disease progression","volume":"19","author":"Klotz","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/B978-0-12-802395-2.00021-3","article-title":"Concepts and classification of neurodegenerative diseases","volume":"145","author":"Kovacs","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1161\/STROKEAHA.113.002880","article-title":"FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection","volume":"44","author":"Kraft","year":"2013","journal-title":"Stroke"},{"key":"B50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1126\/science.279.5356.1552","article-title":"Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1","volume":"279","author":"Lee","year":"1998","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.chest.2023.10.023","article-title":"Ozanimod therapy in patients with COVID-19 requiring oxygen support: a randomized open-label pilot trial","volume":"165","author":"Lellouche","year":"2024","journal-title":"Chest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00702-023-02618-5","article-title":"Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD","volume":"130","author":"Le\u00dfmann","year":"2023","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B54","first-page":"413","article-title":"Efficacy of fingolimod combined with alteplase in acute ischemic stroke and rehabilitation nursing","volume":"32","author":"Liantao","year":"2019","journal-title":"Pak J. Pharm. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.3390\/ijms21176242","article-title":"A sphingosine 1-phosphate gradient is linked to the cerebral recruitment of T helper and regulatory T helper cells during acute ischemic stroke","volume":"21","author":"Lucaciu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s42466-020-00093-x","article-title":"Sphingosine 1-phosphate levels in cerebrospinal fluid after subarachnoid hemorrhage","volume":"2","author":"M\u00e4nner","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"B58","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","article-title":"Ponesimod: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1038\/s41467-024-49893-8","article-title":"Pseudoirreversible inhibition elicits persistent efficacy of a sphingosine 1-phosphate receptor 1 antagonist","volume":"15","author":"Maruyama","year":"2024","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/jof6030142","article-title":"Antifungal drug development: targeting the fungal sphingolipid pathway","volume":"6","author":"McEvoy","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jneuroim.2014.07.010","article-title":"FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation","volume":"274","author":"Mencl","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","article-title":"Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation","volume":"24","author":"Miguez","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuropharm.2018.02.023","article-title":"Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase","volume":"135","author":"Motyl","year":"2018","journal-title":"Neuropharmacology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCRESAHA.120.316711","article-title":"Endothelial S1P1 signaling counteracts infarct expansion in ischemic stroke","volume":"128","author":"Nitzsche","year":"2021","journal-title":"Circ. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2014.03.007","article-title":"FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway","volume":"270","author":"Ntranos","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s1388-1981(02)00147-6","article-title":"Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator","volume":"1582","author":"Okajima","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"B70","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tips.2013.05.002","article-title":"The structure and function of the S1P1 receptor","volume":"34","author":"O'Sullivan","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","article-title":"Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases","volume":"113","author":"O'Sullivan","year":"2017","journal-title":"Neuropharmacology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/ml300396r","article-title":"Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator","volume":"4","author":"Pan","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"B74","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/1440-1681.13483","article-title":"Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection","volume":"48","author":"Pan","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fphar.2020.00077","article-title":"Sphingosine-1-Phosphate receptors modulators decrease signs of neuroinflammation and prevent Parkinson's disease symptoms in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model","volume":"11","author":"P\u00e9pin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","article-title":"Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1080\/14656566.2018.1540592","article-title":"Ozanimod for the treatment of relapsing remitting multiple sclerosis","volume":"19","author":"Rasche","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jnc.13946","article-title":"Fingolimod confers neuroprotection through activation of Rac1 after experimental germinal matrix hemorrhage in rat pups","volume":"140","author":"Rolland","year":"2017","journal-title":"J. Neurochem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.expneurol.2012.12.009","article-title":"Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage","volume":"241","author":"Rolland","year":"2013","journal-title":"Exp. Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","article-title":"Sphingosine 1-phosphate receptor signaling","volume":"78","author":"Rosen","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1165\/rcmb.2006-0383OC","article-title":"Sphingosine-1-phosphate\/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness","volume":"36","author":"Roviezzo","year":"2007","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/glia.24135","article-title":"Neuronal contact upregulates astrocytic sphingosine-1-phosphate receptor 1 to coordinate astrocyte-neuron cross communication","volume":"70","author":"Singh","year":"2022","journal-title":"Glia"},{"key":"B86","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S2468-1253(20)30189-8","article-title":"Ozanimod in Crohn's disease: a promising new player","volume":"5","author":"Sleutjes","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jneuroim.2018.02.016","article-title":"Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis","volume":"318","author":"Smith","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e157738","DOI":"10.1172\/JCI157738","article-title":"Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment","volume":"132","author":"Squillace","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B89","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.3390\/ijms21186463","article-title":"Morpholino analogues of fingolimod as novel and selective S1P1 ligands with in vivo efficacy in a mouse model of experimental antigen-induced encephalomyelitis","volume":"21","author":"Stepanovska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1021\/np2000528","article-title":"Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite","volume":"74","author":"Strader","year":"2011","journal-title":"J. Nat. Prod."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0193236","DOI":"10.1371\/journal.pone.0193236","article-title":"Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus","volume":"13","author":"Taylor Meadows","year":"2018","journal-title":"PLoS One"},{"key":"B92","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ana.25352","article-title":"Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow","volume":"84","author":"Tian","year":"2018","journal-title":"Ann. Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10072-021-05049-w","article-title":"Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis","volume":"42","author":"Tong","year":"2021","journal-title":"Neurol. Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-Phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation","volume":"76","author":"Tsai","year":"2016","journal-title":"Drugs"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e86462","DOI":"10.1172\/jci.insight.86462","article-title":"Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation","volume":"1","author":"Tsai","year":"2016","journal-title":"JCI Insight"},{"key":"B96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12974-023-02706-z","article-title":"Siponimod ameliorates experimental autoimmune neuritis","volume":"20","author":"Uchi","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"B97","article-title":"Hemorrhagic stroke","author":"Unnithan Akadas Jmmehta","year":"2023","journal-title":"StatPearls"},{"key":"B98","doi-asserted-by":"publisher","first-page":"105018","DOI":"10.1016\/j.neuint.2021.105018","article-title":"The S1P(2) receptor regulates blood-brain barrier integrity and leukocyte extravasation with implications for neurodegenerative disease","volume":"146","author":"Xiang","year":"2021","journal-title":"Neurochem. Int."},{"key":"B99","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-021-00250-5","article-title":"A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed","volume":"10","author":"Xu","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"B100","doi-asserted-by":"publisher","first-page":"609679","DOI":"10.3389\/fnagi.2021.609679","article-title":"The therapeutic targets of fingolimod (FTY720) are involved in pathological processes in the frontal cortex of alzheimer's disease patients: a network pharmacology study","volume":"13","author":"Yin","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.18632\/aging.101931","article-title":"Aging and ischemic stroke","volume":"11","author":"Yousufuddin","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41392-023-01688-x","article-title":"Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1177\/1747493017710340","article-title":"Rationale and design of combination of an immune modulator fingolimod with alteplase bridging with mechanical thrombectomy in acute ischemic stroke (FAMTAIS) trial","volume":"12","author":"Zhang","year":"2017","journal-title":"Int. J. Stroke"},{"key":"B104","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12987-022-00356-6","article-title":"Selective sphingosine-1-phosphate receptor 1 modulator attenuates blood-brain barrier disruption following traumatic brain injury by inhibiting vesicular transcytosis","volume":"19","author":"Zhang","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"B105","doi-asserted-by":"publisher","first-page":"966","DOI":"10.14336\/AD.2022.1102","article-title":"Lymphocyte-related immunomodulatory therapy with siponimod (BAF-312) improves outcomes in mice with acute intracerebral hemorrhage","volume":"14","author":"Zhang","year":"2023","journal-title":"Aging Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1096\/fj.201600751R","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinson's disease","volume":"31","author":"Zhao","year":"2017","journal-title":"FASEB J."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e2311803","DOI":"10.1002\/adma.202311803","article-title":"Neutrophil membrane-camouflaged polyprodrug nanomedicine for inflammation suppression in ischemic stroke therapy","volume":"36","author":"Zhao","year":"2024","journal-title":"Adv. Mater"},{"key":"B108","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12974-023-02854-2","article-title":"Prmt5 deficiency inhibits CD4+ T-cell Klf2\/S1pr1 expression and ameliorates EAE disease","volume":"20","author":"Zheng","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"B109","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson's disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.016371","article-title":"Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial","volume":"132","author":"Zhu","year":"2015","journal-title":"Circulation"},{"key":"B111","doi-asserted-by":"publisher","first-page":"104713","DOI":"10.1016\/j.ebiom.2023.104713","article-title":"The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases A\u03b2 clearance in 5XFAD mice","volume":"94","author":"Zhu","year":"2023","journal-title":"EBioMedicine"},{"key":"B112","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-021-02192-1","article-title":"Endothelial glycocalyx in traumatic brain injury associated coagulopathy: potential mechanisms and impact","volume":"18","author":"Zou","year":"2021","journal-title":"J. Neuroinflammation"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:40:22Z","timestamp":1747186822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":112,"alternative-id":["10.3389\/fphar.2025.1516991"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1516991","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1516991"}}